BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Recent Advances in the Management of Myelofibrosis

Case Based Peer Perspectives

Videos

Aaron T. Gerds, MD, MS, provides an overview of the currently available and emerging treatment options for patients with myelofibrosis.

Aaron T. Gerds, MD, MS, details the current treatment options available for patients with high-risk myelofibrosis, and reviews the criteria for risk stratification.

Available Treatment Options for Patients With Higher-Risk Myelofibrosis

Aaron T. Gerds, MD, MS, explains the current remaining unmet needs in the treatment of patients with myelofibrosis.

Current Unmet Needs in the Treatment of Myelofibrosis

Aaron T. Gerds, MD, MS, highlights exciting treatment options on the horizon for patients with myelofibrosis.

Emerging Treatments for Patients With Myelofibrosis

Aaron Gerds, MD, MS, presents the case of a 73-year-old man with myelofibrosis.

Case Presentation: A 73-Year-Old Man with Myelofibrosis (MF)

Aaron Gerds, MD, MS, explains that unlike solid tumors, blood cancers are systemic, so risk stratification models like DIPSS that use readily available data on blood counts and physical exam are more useful prognostically; however, mutation analysis is becoming increasingly important for determining prognosis and targeting therapies.

Risk Stratification of Patients With MF

Aaron Gerds, MD, MS, outlines how first-line treatment choice for myelofibrosis depends on symptoms, spleen size, and blood counts, while second-line choice depends on prior side effects and medical history.

Current Treatment Landscape for Patients With MF

Aaron Gerds, MD, MS, details the use of momelotinib in myelofibrosis treatment.

Momelotinib in Patients With MF

Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.

Monitoring Patients on Treatment for MF

When switching JAK inhibitors for myelofibrosis, Aaron Gerds, MD, MS, advises stopping ruxolitinib and starting the new JAK inhibitor the next day due to its short half-life, though tapering ruxolitinib over 1 week is recommended for patients on higher doses to avoid rebound symptoms; pacritinib and fedratinib have longer half-lives so a 1-week washout can be considered.

Approaches to Switching Therapies for Patients With MF

Aaron Gerds, MD, MS, explains the factors to consider when selecting an appropriate JAK inhibitor for patients with myelofibrosis.

Factors for Consideration When Selecting a JAK Inhibitor for Patients With MF

Aaron Gerds, MD, MS, reviews key safety concerns seen with JAK inhibitors for myelofibrosis treatment.

Safety of Available JAK Inhibitors for Treatment of MF

Aaron Gerds, MD, MS, shares hopes that combination therapies now in trials, along with other novel approaches further down the pipeline like monoclonal antibodies, vaccines, and cellular therapies will likely radically advance treatment over the next 5 to 10 years.

Future of Myelofibrosis Treatments

Emerging Treatments for Patients With Myelofibrosis

EP: 1.Available Treatment Options for Patients With Higher-Risk Myelofibrosis

EP: 2.Current Unmet Needs in the Treatment of Myelofibrosis

EP: 3.Emerging Treatments for Patients With Myelofibrosis

EP: 4.Case Presentation: A 73-Year-Old Man with Myelofibrosis (MF)

EP: 5.Risk Stratification of Patients With MF

EP: 6.Current Treatment Landscape for Patients With MF

EP: 7.Momelotinib in Patients With MF

EP: 8.Monitoring Patients on Treatment for MF

EP: 9.Approaches to Switching Therapies for Patients With MF

EP: 10.Factors for Consideration When Selecting a JAK Inhibitor for Patients With MF

EP: 11.Safety of Available JAK Inhibitors for Treatment of MF

EP: 12.Future of Myelofibrosis Treatments